In re Generic Pharmaceuticals Pricing Antitrust Litigation
STATUS — Ongoing
PRACTICE — Antitrust
CASE — MDL No. 2724, U.S. District Court for the Eastern District of Pennsylvania
The firm is currently leading the largest antitrust multidistrict litigation now pending in the country, following the Honorable Cynthia M. Rufe’s appointment of FKB’s Roberta Liebenberg to serve as Lead Counsel for the end-payer plaintiffs. The plaintiffs allege that leading generic pharmaceutical manufacturers fixed prices for more than 180 generic drugs.
Complaints related to two of the drugs—clobetasol and clomipramine—are proceeding as bellwethers. In 2024 and 2025, the end-payer plaintiffs achieved favorable Daubert and class certification decisions relating to these bellwether drugs. To date, they have secured more than $500 million in settlements.
